Topic:

Partnering

Latest Headlines

Latest Headlines

Medtronic looks beyond Type 1 with a diabetes reorg

Medtronic's fastest growing business is in diabetes, which gained 10% to $430 million in the most recent quarter over a year ago. Now the medical device giant is looking to expand beyond its dominance in Type 1 diabetes that is based on the success of its insulin pump MiniMed. During an earnings call, Medtronic disclosed that it reorganized its diabetes group last quarter.

Clovis taps GlaxoSmithKline to team up on lung cancer

Clovis Oncology has signed a deal to test whether its lead drug can make a difference in lung cancer when paired with GlaxoSmithKline's melanoma treatment Mekinist.

Medtronic partners with DaVita, rolls out CRT meta-analysis data

Dialysis provider DaVita HealthCare Partners has partnered with Medtronic for a pilot program to study cardiac arrhythmias in end-stage renal disease patients receiving dialysis. It will use the tiny implantable cardiac monitor, Linq, which Medtronic launched early this year.

Boehringer taps WellPoint's outcomes data to develop new a-fib drugs

Boehringer Ingelheim is working with managed care giant WellPoint in an effort to use real-world data to inform the development of new treatments of atrial fibrillation, keeping up with a sweeping trend in cardiovascular R&D.

J&J bets up to $935M that Geron's drug can shake a checkered past

Days after finally getting the FDA's go-ahead to resume the stop-and-start development of its lead candidate, Geron has signed a deal to cut Johnson & Johnson in on the process, putting the biotech in line for as much as $935 million if all goes according to plan.

Xerox invests in HealthSpot, a telemedicine provider

Xerox, best known for its copy machines and document management systems, is investing in HealthSpot, a telemedicine provider that sets up kiosks that connect patients with physicians.

Takeda's Millennium re-ups with Presage on cancer drug combo effort

Whatever Cambridge, MA-based Millennium learned over the past two years it's been collaborating with Presage Biosciences, the experience must have been rewarding.

Servier gambling up to $1B-plus on Intarcia's PhIII diabetes drug/device

Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France's Servier.

GE Healthcare lends imaging tech to Takeda for Dx partnership

As chronic liver disease numbers continue to skyrocket, diagnostics heavyweight GE Healthcare and Japanese-based Takeda are teaming up to develop new drugs to counter the trend.

Takeda recruits GE to help discover new liver treatments

The growing scourge of liver disease in the developed world has spurred a frenzied race among drug developers to ferret out new therapies, and Takeda, new to the field, has recruited the diagnostics experts at GE Healthcare to shepherd its early R&D efforts.